B-Cell Chronic Lymphocytic Leukemia

Also known as: B-cell Chronic Lymphocytic Leukemia / Chronic lymphocytic leukemia / Leukemia lymphocytic chronic / CLL / Chronic lymphoid leukaemia / Lymphoid leukaemia, chronic / Lymphoid leukemia, chronic / Chronic lymphatic leukaemia / Chronic lymphoid leukemia / Leukaemia lymphocytic chronic / Chronic lymphatic leukemia / Chronic lymphocytic leukaemia NOS / Leukaemias chronic lymphocytic / Chronic lymphocytic leukaemia / Leukemia, Lymphocytic, Chronic, B-Cell / Lymphoplasmacytic leukemia / B-cell chronic lymphocytic leukaemia

DrugDrug NameDrug Description
DB00087AlemtuzumabHumanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.
DB00028Immune Globulin HumanIntravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.
DrugDrug NameTargetType
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00028Immune Globulin HumanHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00028Immune Globulin HumanHigh affinity immunoglobulin gamma Fc receptor IBtarget
DB00028Immune Globulin HumanComplement C3target
DB00028Immune Globulin HumanComplement C4-Atarget
DB00028Immune Globulin HumanComplement C4-Btarget
DB00028Immune Globulin HumanComplement C5target
DrugDrug NamePhaseStatusCount
DB00041Aldesleukin1Completed1
DB12442Alvespimycin1Terminated1
DB03496Alvocidib1Completed1
DB03496Alvocidib1Terminated1
DB00928Azacitidine1Completed1
DB12359BIIB0211Terminated1
DB06769Bendamustine1Terminated1
DB12109CPI-6131Terminated1
DB08889Carfilzomib1Completed1
DB00493Cefotaxime1Completed1
DB00291Chlorambucil1Completed1
DB00531Cyclophosphamide1Completed1
DB00531Cyclophosphamide1Not Yet Recruiting1
DB00199Erythromycin1Completed1
DB00773Etoposide1Terminated1
DB01073Fludarabine1Completed1
DB01073Fludarabine1Not Yet Recruiting1
DB01073Fludarabine1Terminated1
DB06185Forodesine1Terminated1
DB09053Ibrutinib1Completed2
DB11694Ilorasertib1Completed1
DB00480Lenalidomide1Terminated1
DB12191Obatoclax1Terminated1
DB08935Obinutuzumab1Completed1
DB00526Oxaliplatin1Terminated1
DB00073Rituximab1Completed1
DB00073Rituximab1Terminated3
DB06398Tanespimycin1Terminated1
DB13881Tisagenlecleucel1Completed1
DB06273Tocilizumab1Completed1
DB00582Voriconazole1Completed1
DB00087Alemtuzumab1 / 2Active Not Recruiting1
DB03496Alvocidib1 / 2Completed1
DB00262Carmustine1 / 2Active Not Recruiting1
DB00493Cefotaxime1 / 2Recruiting1
DB00531Cyclophosphamide1 / 2Recruiting2
DB00987Cytarabine1 / 2Active Not Recruiting1
DB12731Daporinad1 / 2Completed1
DB00997Doxorubicin1 / 2Recruiting1
DB00773Etoposide1 / 2Active Not Recruiting1
DB00773Etoposide1 / 2Recruiting1
DB05076Fenretinide1 / 2Terminated1
DB01073Fludarabine1 / 2Recruiting1
DB09053Ibrutinib1 / 2Completed2
DB09053Ibrutinib1 / 2Recruiting2
DB06186Ipilimumab1 / 2Terminated1
DB00480Lenalidomide1 / 2Recruiting1
DB01042Melphalan1 / 2Active Not Recruiting1
DB06650Ofatumumab1 / 2Completed1
DB00635Prednisone1 / 2Recruiting1
DB00073Rituximab1 / 2Active Not Recruiting1
DB00073Rituximab1 / 2Recruiting2
DB00073Rituximab1 / 2Terminated1
DB12636Samalizumab1 / 2Completed1
DB00541Vincristine1 / 2Recruiting1
DB00087Alemtuzumab2Completed3
DB00087Alemtuzumab2Recruiting1
DB00087Alemtuzumab2Unknown Status1
DB03496Alvocidib2Completed1
DB03496Alvocidib2Terminated1
DB11851Bafetinib2Completed1
DB00112Bevacizumab2Completed1
DB00112Bevacizumab2Withdrawn1
DB04849Cediranib2Completed1
DB00493Cefotaxime2Completed1
DB00531Cyclophosphamide2Completed2
DB00531Cyclophosphamide2Unknown Status1
DB00091Cyclosporine2Completed2
DB01073Fludarabine2Completed4
DB01073Fludarabine2Withdrawn1
DB01611Hydroxychloroquine2Terminated1
DB09053Ibrutinib2Enrolling by Invitation1
DB00563Methotrexate2Completed1
DB00688Mycophenolate mofetil2Completed1
DB05764Navitoclax2Withdrawn1
DB06650Ofatumumab2Completed1
DB00552Pentostatin2Completed1
DB00552Pentostatin2Unknown Status1
DB06638Quarfloxin2Withdrawn1
DB00073Rituximab2Completed3
DB00073Rituximab2Unknown Status2
DB00073Rituximab2Withdrawn1
DB01268Sunitinib2Completed1
DB00864Tacrolimus2Completed1
DB06287Temsirolimus2Completed1
DB01041Thalidomide2Completed1
DB02546Vorinostat2Completed1
DB00087Alemtuzumab3Completed1
DB00291Chlorambucil3Active Not Recruiting1
DB00531Cyclophosphamide3Completed1
DB01073Fludarabine3Completed2
DB00480Lenalidomide3Active Not Recruiting2
DB00552Pentostatin3Completed1
DB00073Rituximab3Completed1
DB00087AlemtuzumabNot AvailableUnknown Status1
DB00188BortezomibNot AvailableActive Not Recruiting1
DB00091CyclosporineNot AvailableActive Not Recruiting1
DB00099FilgrastimNot AvailableActive Not Recruiting1
DB01073FludarabineNot AvailableActive Not Recruiting1
DB09053IbrutinibNot AvailableApproved for Marketing1
DB00480LenalidomideNot AvailableTerminated1
DB00688Mycophenolate mofetilNot AvailableActive Not Recruiting1